Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Sinomenine hydrochloride improves DSS-induced colitis in mice through inhibition of the Notch signaling pathway.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X (Electronic) Linking ISSN: 1471230X NLM ISO Abbreviation: BMC Gastroenterol Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
    • Abstract:
      Objective: To study the therapeutic effect of sinomenine hydrochloride (SH) on dextran sodium sulfate (DSS)-induced colitis in mice as an animal model and the changes of Notch signaling pathway in colon tissue of mice after treatment.
      Methods: Twenty-four mice were randomly divided into control group, model group, SH low-dose group (20 mg/kg) and SH high-dose group (60 mg/kg), with 6 mice in each group. Disease activity index (DAI), colonic mucosal injury index and colonic histopathological score were calculated. The expression levels of related genes, proteins in Notch signaling pathway and inflammatory factors were quantified.
      Results: SH can significantly reduce the symptoms of colitis mice, and can significantly reduce the DAI score (Model: 3.44 ± 0.27; SH-20: 2.50 ± 0.18; SH-60: 1.89 ± 0.17; P < 0.001) and histopathological injury degree (Model: 7.67 ± 0.52; SH-20: 5.17 ± 0.75, P < 0.01; SH-60: 3.33 ± 0.52, P < 0.001). SH can down-regulate the expression levels of Notch1, NICD1, Jagged1 and Hes1 proteins in colon tissue of colitis mice (Model: 1.92 ± 0.16, 1.83 ± 0.21, 2.23 ± 0.22, 1.91 ± 0.17; SH-20: 1.56 ± 0.12, 1.39 ± 0.13, 1.58 ± 0.12, 1.38 ± 0.11; SH-60: 1.24 ± 0.09, 1.23 ± 0.10, 1.23 ± 0.11, 1.22 ± 0.09; P < 0.01), and reduce the contents of serum pro-inflammatory cytokines TNF-α, IL-1β and IL-6 (Model: 718.53 ± 81.81, 51.62 ± 2.80, 444.07 ± 67.77; SH-20: 544.72 ± 90.03, 34.10 ± 2.90, 345.43 ± 43.40; SH-60: 434.11 ± 71.75, 29.44 ± 3.70, 236.11 ± 29.35; P < 0.001).
      Conclusion: The therapeutic effect of SH on DSS-induced colitis in mice may be related to inhibiting the overactivation of Notch signaling pathway.
      Competing Interests: Declarations. Ethics approval and consent to participate: This study has been approved by the Animal Ethics Committee of Bengbu Medical University (No.2021336). All experiments were conducted in accordance with relevant guidelines and regulations. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
      (© 2024. The Author(s).)
    • References:
      Lancet. 2023 Aug 12;402(10401):571-584. (PMID: 37573077)
      Trends Endocrinol Metab. 2018 Jan;29(1):42-54. (PMID: 29162310)
      Expert Opin Drug Saf. 2016;15(4):457-65. (PMID: 26789102)
      Am J Case Rep. 2017 Sep 06;18:959-962. (PMID: 28874654)
      Cochrane Database Syst Rev. 2016 May 09;(5):CD000544. (PMID: 27158764)
      Circ Res. 2021 May 28;128(11):1728-1746. (PMID: 33998272)
      Biomed Pharmacother. 2020 Apr;124:109847. (PMID: 31981944)
      Am Fam Physician. 2013 May 15;87(10):699-705. (PMID: 23939448)
      Front Cardiovasc Med. 2021 Oct 01;8:749113. (PMID: 34660748)
      Lancet. 2018 Dec 23;390(10114):2769-2778. (PMID: 29050646)
      World J Gastrointest Pharmacol Ther. 2016 Aug 6;7(3):353-60. (PMID: 27602236)
      Clin Exp Immunol. 2006 Mar;143(3):550-9. (PMID: 16487255)
      Inflamm Bowel Dis. 2021 Mar 15;27(4):522-529. (PMID: 32793962)
      Ann Rheum Dis. 2015 Jan;74(1):267-74. (PMID: 24255545)
      Pharmacol Ther. 2002 Oct;96(1):23-43. (PMID: 12441176)
      Hematology. 2021 Dec;26(1):734-740. (PMID: 34555308)
      Front Pharmacol. 2017 Jun 23;8:400. (PMID: 28690543)
      Protein Cell. 2016 Mar;7(3):159-74. (PMID: 26936847)
      Mediators Inflamm. 2004 Jun;13(3):181-7. (PMID: 15223609)
      Nature. 2020 Jun;582(7811):259-264. (PMID: 32499639)
      Phytomedicine. 2021 Sep;90:153631. (PMID: 34253428)
      World J Gastroenterol. 2016 Nov 14;22(42):9300-9313. (PMID: 27895418)
      Life Sci. 2021 Jan 15;265:118855. (PMID: 33278392)
      Front Immunol. 2021 Nov 23;12:766845. (PMID: 34887862)
      Phytomedicine. 2020 Mar;68:153182. (PMID: 32065953)
      Pharmacol Res. 2021 May;167:105513. (PMID: 33617975)
      PLoS Pathog. 2011 Nov;7(11):e1002341. (PMID: 22072963)
      Cell Prolif. 2019 Mar;52(2):e12547. (PMID: 30657238)
      PLoS Biol. 2020 Oct 5;18(10):e3000850. (PMID: 33017398)
      Int J Mol Med. 2013 Nov;32(5):1051-62. (PMID: 24048326)
      Kidney Int. 2010 Sep;78(5):514-22. (PMID: 20531454)
      EMBO J. 2019 Feb 15;38(4):. (PMID: 30635334)
      Eur J Pharmacol. 2019 Jul 5;854:101-108. (PMID: 30954565)
      Int J Pharm. 2022 Apr 5;617:121628. (PMID: 35245636)
      J Biomed Sci. 2021 May 9;28(1):36. (PMID: 33966637)
      Aliment Pharmacol Ther. 2011 May;33(9):987-95. (PMID: 21366636)
      Cells. 2020 Jan 02;9(1):. (PMID: 31906482)
      Sci Rep. 2021 Sep 21;11(1):18726. (PMID: 34548536)
      Cochrane Database Syst Rev. 2012 Nov 14;11:CD004118. (PMID: 23152224)
      Front Pharmacol. 2021 Mar 18;12:639458. (PMID: 33841156)
      J Crohns Colitis. 2010 Oct;4(4):355-66. (PMID: 21122530)
      Int Immunopharmacol. 2019 Mar;68:242-251. (PMID: 30743078)
      Lancet. 2012 Nov 3;380(9853):1606-19. (PMID: 22914296)
      Dtsch Arztebl Int. 2020 Aug 17;117(33-34):564-574. (PMID: 33148393)
      Int Immunopharmacol. 2017 Sep;50:251-262. (PMID: 28711031)
      Drug Res (Stuttg). 2021 Sep;71(7):379-387. (PMID: 33728619)
      Free Radic Biol Med. 2016 Mar;92:90-99. (PMID: 26795599)
      Gastroenterol Clin North Am. 2020 Dec;49(4):643-654. (PMID: 33121686)
      Clin J Am Soc Nephrol. 2021 Aug;16(8):1264-1271. (PMID: 33853841)
      Mol Pain. 2018 Jan-Dec;14:1744806918793232. (PMID: 30027795)
      J Am Vet Med Assoc. 2013 Mar 15;242(6):714-6. (PMID: 23445278)
      Drug Dev Res. 2021 Apr;82(2):251-258. (PMID: 33006164)
      Curr Med Sci. 2020 Feb;40(1):130-137. (PMID: 32166675)
      Exp Ther Med. 2021 Nov;22(5):1287. (PMID: 34630642)
      J Exp Med. 2012 Aug 27;209(9):1595-609. (PMID: 22891275)
      Adv Clin Exp Med. 2017 Jan-Feb;26(1):57-61. (PMID: 28397433)
      Biomed Pharmacother. 2021 Jan;133:110937. (PMID: 33217689)
      Pharmacol Res. 2022 Jan;175:105977. (PMID: 34798265)
    • Grant Information:
      No. KJ2021A0813 for Natural Science Research Project of Anhui Educational Committee; No.2022a05020022 Anhui Provincial Key Research and Development Project; No.KJ2018A0217 the Program for Natural Science Research Project of Anhui Educational Committee; No.Byyfykj201804 Science and Technology Development Fund Project of the First Affiliated Hospital of Bengbu Medical University
    • Contributed Indexing:
      Keywords: Disease activity index; Notch signaling pathway; Sinomenine hydrochloride; Ulcerative colitis
    • Accession Number:
      63LT81K70N (sinomenine)
      0 (Morphinans)
      9042-14-2 (Dextran Sulfate)
      0 (Tumor Necrosis Factor-alpha)
      0 (Receptors, Notch)
      0 (Jagged-1 Protein)
      0 (Interleukin-6)
      0 (Receptor, Notch1)
      0 (Interleukin-1beta)
      0 (Transcription Factor HES-1)
    • Publication Date:
      Date Created: 20241218 Date Completed: 20241219 Latest Revision: 20250104
    • Publication Date:
      20250104
    • Accession Number:
      PMC11653842
    • Accession Number:
      10.1186/s12876-024-03546-8
    • Accession Number:
      39695403